PRELUDE THERAPEUTICS INC Tax Withholding Paid on Stock Awards
PRELUDE THERAPEUTICS INC (PRLD) reported Tax Withholding Paid on Stock Awards of $64.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $13.00K, a 550.00% increase year-over-year.
- PRELUDE THERAPEUTICS INC payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $51.00K, a 920.00% increase year-over-year.
- PRELUDE THERAPEUTICS INC payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $5.00K, a 28.57% decline year-over-year.
- PRELUDE THERAPEUTICS INC payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $5.00K, a 61.54% decline year-over-year.
- PRELUDE THERAPEUTICS INC payment, tax withholding, share-based payment arrangement for fiscal 2025 was $17.00K, a 68.52% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC payment, tax withholding, share-based payment arrangement for fiscal 2024 was $54.00K, a 217.65% increase from fiscal 2023.
- PRELUDE THERAPEUTICS INC payment, tax withholding, share-based payment arrangement for fiscal 2023 was $17.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $64.00K 10-Q · filed 2026-08-11 | $69.00K derived: sum of 3 quarters · filed 2026-08-11 | $74.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $51.00K 10-Q · filed 2026-05-12 | $56.00K derived: sum of 2 quarters · filed 2026-05-12 | $61.00K derived: sum of 3 quarters · filed 2026-05-12 | $63.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $10.00K derived: sum of 2 quarters · filed 2026-03-10 | $12.00K derived: sum of 3 quarters · filed 2026-08-11 | $17.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $7.00K derived: sum of 2 quarters · filed 2026-08-11 | $12.00K 10-Q · filed 2025-11-12 | $19.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $7.00K 10-Q · filed 2026-08-11 | $14.00K derived: sum of 3 quarters · filed 2026-08-11 | $27.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $5.00K 10-Q · filed 2026-05-12 | $12.00K derived: sum of 2 quarters · filed 2026-05-12 | $25.00K derived: sum of 3 quarters · filed 2026-05-12 | $43.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $20.00K derived: sum of 2 quarters · filed 2026-03-10 | $38.00K derived: sum of 3 quarters · filed 2026-03-10 | $54.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $31.00K derived: sum of 2 quarters · filed 2025-11-12 | $47.00K 10-Q · filed 2025-11-12 | $48.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $34.00K 10-Q · filed 2025-08-14 | $35.00K derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | $16.00K 10-Q · filed 2025-05-06 | $17.00K derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $17.00K 10-K · filed 2025-03-10 | ||
| 2023-09-30 | $16.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |